arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BioXcel Therapeutics, Inc.

BTAI
$0.07 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Excellent
Bullish
auto_awesome

Analytical Summary

BioXcel Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.1M
Dividend Yield —
Revenue Growth 51.7% ↗
Op. Margin —
ROIC 73.1% ↘
FCF / Share $-0.20 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.90
info Valuation on last close. End-of-day price, Sep 4, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$182.00K
↑ +51.7% —
Net Income Profit after all expenses
$-12.69M
↓ -75.0% —
FCF / Share Free cash flow per share
$-0.20
↑ +59.8% —
Long-Term Debt Long-term obligations
$104.45M
↑ +4.2% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
98
Financial Health ↑
70
Cash Quality ↑
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 39 quarters